Antibiotic-resistant infections in cancer patients have become a growing concern over the past five years, with methicillin-resistant Staphylococcus aureus (MRSA) being the most common in those receiving chemotherapy, according to a new survey sponsored by Amgen Inc. and the Centers for Disease Control and Prevention (CDC), which have teamed in a three-year initiative to tackle the problem. (BioWorld Today)